RICHMOND, Calif., July 12, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that members of the Company's research and development team will participate in the following scientific conferences in July.
American Society of Hematology (ASH) Workshop on Genome Editing, Washington, D.C., July 14-15, 2016 Edward Rebar, Ph.D., Sangamo's vice president of technology, and Dale Ando, vice president of therapeutic development and chief medical officer, are invited speakers at the workshop, which is focused on the mechanistic aspects of genome editing and its clinical applications to blood disorders. In his presentation, Dr. Rebar will discuss the design and application of new zinc finger nuclease (ZFN) architectures that increase the targeting range of Sangamo's ZFN platform. Dr. Ando's presentation will focus on the Company's development of the first-in-man clinical trial of genome editing, for hemophilia B, and other recent therapeutic applications.
MPS 2016 - 14th International Symposium on MPS and Related Diseases, Bonn, Germany, July 14-17, 2016 Thomas Wechsler, Ph.D., Sangamo's director of rare diseases, is scheduled to present the preclinical data that supported the Company's Investigational New Drug (IND) applications for MPS I (Hurler syndrome) and MPS II (Hunter syndrome).
World Federation of Hemophilia (WFH) 2016 World Congress, Orlando, FL, July 24-28, 2016 Brigit Riley, Ph.D., Sangamo's director of discovery and translational research, will present an update on the Company's hemophilia A program.
22nd Annual Meeting of Japan Society of Gene and Cell Therapy (JSGCT), Tokyo, Japan, July 28-30, 2016 Thomas Wechsler, Ph.D., is an invited speaker and will discuss the Company's In Vivo Protein Replacement Platform™ (IVPRP) genome editing approach and its application to lysosomal storage disorders.
Webcasting services are not provided at the conferences listed above.
About Sangamo Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures® for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic genome editing and gene regulation. The Company's proprietary In Vivo Protein Replacement Platform™ (IVPRP) approach is focused on monogenic diseases, including hemophilia and lysosomal storage disorders. Based on its proprietary IVPRP approach, Sangamo is initiating Phase 1/2 clinical trials for hemophilia B, the first in vivo genome editing application cleared by the FDA, MPS I and MPS II. In addition, Sangamo has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics® for the treatment of HIV/AIDS (SB-728). The Company has also formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, and with Shire International GmbH to develop therapeutics for Huntington's disease. It has established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.